OTR3 is a leading biotechnology brand specializing in Matrix Therapy. Founded by renowned biologists Prof Denis Barritault and Prof Jean-Pierre Caruelle, OTR3 is at the forefront of regenerative medicine with its groundbreaking RGTA® Technology (ReGeneraTing Agents). This therapy offers a new class of therapeutic solutions for various medical conditions.

OTR3 currently offers three innovative products. Cacipliq® is a CE marked medical device designed to enhance wound healing. Clerapliq provides effective treatment for corneal lesions in animals, while Dermapliq addresses skin lesions in animals.

These products utilize the patented worldwide RGTA® Technology, providing safe and cutting-edge solutions. With a focus on extensive research and development, OTR3 aims to explore the full potential of RGTA® Technology. By developing new indications and healthcare products, the brand strives to bring significant benefits to a large number of patients.

OTR3's dedicated team, including industry veterans and experienced professionals, is committed to driving the development of novel regenerative matrix therapies. Overall, OTR3's mission is to deliver comprehensive regenerative solutions for dermatological and neurological diseases with significant unmet medical needs and contribute to the pipeline of future indications